


CLAIMS

1. The use of a compound of formula (I):



5

(I)

wherein:

Ring A is selected from carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^9 ;

- 10 **R^1** is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl) $_2$ amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl) $_2$ carbamoyl, C_{1-4} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl,

- 15 N,N -(C_{1-4} alkyl) $_2$ sulphamoyl, C_{1-4} alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclyl C_{0-4} alkylene-Z- and heterocyclyl C_{0-4} alkylene-Z-; wherein R^1 may be optionally substituted on carbon by one or more groups selected from R^3 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^4 ;

- 20 **n** is 0-5; wherein the values of R^1 may be the same or different;

X is a direct bond, -C(O)-, -S(O) $_2$ -, -C(O)NR 11 -, -C(S)NR 11 -, -C(O)O-, -C(=NR 11)- or -CH $_2$ -; wherein **R^{11}** is selected from hydrogen, C_{1-4} alkyl, carbocyclyl and heterocyclyl;

Y is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, carbocyclyl or heterocyclyl; wherein **Y** may be optionally substituted on carbon by one or more R^2 ; wherein if said

- 25 heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^5 ;

R^2 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino,

N,N-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, *N*-(C₁₋₄alkyl)carbamoyl,
N,N-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl,
 C₁₋₄alkoxycarbonylamino, C₁₋₄alkoxycarbonyl-*N*-(C₁₋₄alkyl)amino, *N*-(C₁₋₄alkyl)sulphamoyl,
N,N-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, aminothiocabonylthio,

5 *N*-(C₁₋₄alkyl)aminothiocabonylthio, *N,N*-(C₁₋₄alkyl)₂aminothiocabonylthio, carbocyclyl,
 heterocyclyl, carbocyclylC₀₋₄alkylene-Z- and heterocyclylC₀₋₄alkylene-Z-; wherein R² may be
 optionally substituted on carbon by one or more groups selected from R⁶; and wherein if said
 heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group
 selected from R⁷;

10 R³ and R⁶ are independently selected from halo, nitro, cyano, hydroxy, amino,
 carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C₁₋₄alkyl,
 C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, *N*-(C₁₋₄alkyl)amino,
N,N-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, *N*-(C₁₋₄alkyl)carbamoyl,
N,N-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl,

15 C₁₋₄alkoxycarbonylamino, C₁₋₄alkoxycarbonyl-*N*-(C₁₋₄alkyl)amino, *N*-(C₁₋₄alkyl)sulphamoyl,
N,N-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, carbocyclyl, heterocyclyl,
 carbocyclylC₀₋₄alkylene-Z- and heterocyclylC₀₋₄alkylene-Z-; wherein R³ and R⁶ may be
 independently optionally substituted on carbon by one or more R⁸; and wherein if said
 heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group

20 selected from R¹³;

R⁴, R⁵, R⁷, R⁹ and R¹³ are independently selected from C₁₋₄alkyl, C₁₋₄alkanoyl,
 C₁₋₄alkylsulphonyl, C₁₋₄alkoxycarbonyl, carbamoyl, *N*-(C₁₋₄alkyl)carbamoyl,
N,N-(C₁₋₄alkyl)₂carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

R⁸ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl,
 25 amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl,
 acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino,
 acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl,
N,N-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl,
 ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl,
 30 *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl
 or *N*-methyl-*N*-ethylsulphamoyl;

Z is -S(O)_a-, -O-, -NR¹⁰-, -C(O)-, -C(O)NR¹⁰-, -NR¹⁰C(O)-, -OC(O)NR¹⁰- or
 -SO₂NR¹⁰-; wherein a is 0 to 2; wherein R¹⁰ is selected from hydrogen and C₁₋₄alkyl;

- 47 -

R^{12} is hydroxy, methyl, ethyl, propyl or trifluoromethyl;

m is 0 or 1;

q is 0 or 1;

or a pharmaceutically acceptable salt thereof;

5 in the manufacture of a medicament for use in the inhibition of 11 β HSD1.

2. The use of a compound according to claim 1, wherein ring A is aryl or heteroaryl; wherein if the heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^9 as defined in claim 1.

10

3. The use of a compound according to either claim 1 or claim 2 wherein R^1 is selected from halo or C_{1-4} alkyl.

15

4. The use of a compound according to any one of claims 1 to 3 wherein n is 0, 1, 2 or 3.

5. The use of a compound according to any one of claims 1 to 4 wherein X is -C(O)- or -S(O)₂-.

20

6. The use of a compound according to any one of claims 1 to 5 wherein Y is carbocyclyl or heterocyclyl; wherein Y may be optionally substituted on carbon by one or more R^2 as defined in claim 1 and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^5 as defined in claim 1.

25

7. The use of a compound according to any one of claims 1 to 5 wherein Y is hydrogen, phenyl, thienyl, isopropyl, methyl, *t*-butyl, furyl, cyclopropyl, cyclohexyl, quinolinyl, benzothienyl, 1,2,5-thiadiazolyl, morpholino, pyridyl, tetrahydrofuryl or indolyl; wherein Y may be optionally substituted on carbon by one or more R^2 as defined in claim 1.


30

8. The use of a compound according to any one of claims 1 to 7 wherein R^2 is selected from halo, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, *N*-(C_{1-4} alkyl)amino or

- 48 -

carbocyclyl; wherein R^2 may be optionally substituted on carbon by one or more halo groups.

9. The use of a compound according to any one of claims 1 to 4 wherein X and Y together form hydrogen, *t*-butoxycarbonyl, cyclopropylcarbonyl, cyclohexylcarbonyl, 4-fluorobenzoyl, 2,5-difluorobenzoyl, 2-chlorobenzoyl, 2-cyanobenzoyl, 4-cyanobenzoyl, 4-methoxybenzoyl, 4-ethoxybenzoyl, 4-isopropoxybenzoyl, 4-*t*-butoxybenzoyl, 4-difluoromethoxybenzoyl, 2-trifluoromethoxybenzoyl, 3-trifluoromethoxybenzoyl, 4-trifluoromethoxybenzoyl, 4-methylaminobenzoyl, 4-fluorobenzylcarbonyl, thien-2-ylcarbonyl, 5-chlorothien-2-ylcarbonyl, fur-2-ylcarbonyl, 5-trifluoromethylfur-2-ylcarbonyl, morpholinocarbonyl, 1,2,5-thiadiazol-3-ylcarbonyl, quinolin-2-ylcarbonyl, quinolin-3-ylcarbonyl, pyrid-2-ylcarbonyl, tetrahydrofur-2-ylcarbonyl, indol-6-ylcarbonyl, benzothien-2-ylcarbonyl, isopropylsulphonyl, 4-fluorophenylsulphonyl, 2-trifluoromethylphenylsulphonyl or thien-2-ylsulphonyl.
10. The use of a compound according to any one of claims 1 to 9 wherein R^{12} is hydroxy, methyl, ethyl or trifluoromethyl.
11. The use of a compound according to any one of claims 1 to 10 wherein *m* is 1.
12. The use of a compound according to any one of claims 1 to 11 wherein *q* is 0.
13. A compound of formula (IA'):



wherein:

Ring A is selected from phenyl, pyridyl, thienyl, furyl or thiazolyl;

- 49 -

R¹ is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, *N*-(C₁₋₄alkyl)carbamoyl, *N,N*-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl, *N*-(C₁₋₄alkyl)sulphamoyl, *N,N*-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein **R¹** may be optionally substituted on carbon by one or more groups selected from **R³**; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from **R⁴**;

10 **n** is 0-5; wherein the values of **R¹** may be the same or different;

X is a -C(O)-, -S(O)₂-, -C(O)NR¹¹-, -C(S)NR¹¹-, -C(O)O- or -C(=NR¹¹)-; wherein **R¹¹** is selected from hydrogen, C₁₋₄alkyl, carbocyclyl and heterocyclyl;

Y is C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl or heterocyclyl; wherein **Y** may be optionally substituted on carbon by one or more **R²**; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from **R⁵**;

R² is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, *N*-(C₁₋₄alkyl)carbamoyl, *N,N*-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl, C₁₋₄alkoxycarbonylamino, C₁₋₄alkoxycarbonyl-*N*-(C₁₋₄alkyl)amino, *N*-(C₁₋₄alkyl)sulphamoyl, *N,N*-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, aminothiocabonylthio, *N*-(C₁₋₄alkyl)aminothiocabonylthio, *N,N*-(C₁₋₄alkyl)₂aminothiocabonylthio, carbocyclyl or heterocyclyl; wherein **R²** may be optionally substituted on carbon by one or more groups selected from **R⁶**; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from **R⁷**;

R³ and **R⁶** are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, *N*-(C₁₋₄alkyl)carbamoyl, *N,N*-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl, C₁₋₄alkoxycarbonylamino, C₁₋₄alkoxycarbonyl-*N*-(C₁₋₄alkyl)amino, *N*-(C₁₋₄alkyl)sulphamoyl, *N,N*-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein

- 50 -

R^3 and R^6 may be independently optionally substituted on carbon by one or more R^8 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{13} ;

R^4 , R^5 , R^7 and R^{13} are independently selected from C_{1-4} alkyl, C_{1-4} alkanoyl,
 5 C_{1-4} alkylsulphonyl, C_{1-4} alkoxycarbonyl, carbamoyl, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)₂carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

R^8 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, N -methyl- N -ethylamino,
 10 acetylaminomethyl, N -methylcarbamoyl, N -ethylcarbamoyl, N,N -dimethylcarbamoyl, N,N -diethylcarbamoyl, N -methyl- N -ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N -methylsulphamoyl, N -ethylsulphamoyl, N,N -dimethylsulphamoyl, N,N -diethylsulphamoyl or N -methyl- N -ethylsulphamoyl;

15 R^{12} is hydroxy, methyl, ethyl, propyl or trifluoromethyl;

m is 0 or 1;

q is 0 or 1;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not 1-acetyl-3-(4-fluorobenzoyl)piperidine; 1-acetyl-3-
 20 (4-dimethylaminobenzoyl)piperidine; 1-(4-nitrobenzoyl)-3-(4-fluorobenzoyl)piperidine; 1-(4-aminobenzoyl)-3-(4-fluorobenzoyl)piperidine; 1-acetyl-3-(4-phthalimidobenzoyl)piperidine; 1-(benzoyl)-3-(4-mesylaminobenzoyl)piperidine; 1-(*t*-butoxycarbonyl)-3-(4-aminobenzoyl)piperidine; or 1,3-dibenzoylpiperidine.

25 14. A compound according to claim 13 wherein R^1 is selected from halo or C_{1-4} alkyl.

15. A compound according to either claim 13 or 14 wherein n is 0, 1, 2 or 3.

16. A compound according to any one of claims 13 to 15 wherein X is $-C(O)-$ or $-S(O)_2-$.
 30

17. A compound according to any one of claims 13 to 16 wherein Y is carbocyclyl or heterocyclyl; wherein Y may be optionally substituted on carbon by one or more

- 51 -

R² as defined in claim 1 and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R⁵ as defined in claim 1.

- 5 18. A compound according to any one of claims 13 to 17 wherein Y is phenyl, thienyl, isopropyl, *t*-butyl, furyl, cyclopropyl, cyclohexyl, quinolinyl or benzothienyl; wherein Y may be optionally substituted on carbon by one or more R² as defined in claim 1.
- 10 19. A compound according to any one of claims 13 to 18 wherein R² is a substituent on carbon and is selected from halo, cyano, C₁₋₄alkyl or C₁₋₄alkoxy; wherein R² may be optionally substituted on carbon by one or more halo groups.
- 15 20. A compound according to any one of claims 13 to 19 wherein X and Y together form *t*-butoxycarbonyl, cyclopropylcarbonyl, cyclohexylcarbonyl, benzoyl, 4-fluorobenzoyl, 2,5-difluorobenzoyl, 2-chlorobenzoyl, 4-chlorobenzoyl, 2-cyanobenzoyl, 4-ethoxybenzoyl, 4-isopropoxybenzoyl, 4-difluoromethoxybenzoyl, 2-trifluoromethoxybenzoyl, 3-trifluoromethoxybenzoyl, thien-2-ylcarbonyl, 20 5-trifluoromethylfur-2-ylcarbonyl, quinoline-2-ylcarbonyl, benzothien-2-ylcarbonyl, isopropylsulphonyl, 4-fluorophenylsulphonyl or thien-2-ylsulphonyl.
- 25 21. A compound according to any one of claims 13 to 20 wherein R¹² is hydroxy, methyl, ethyl or trifluoromethyl.
22. A compound according to any one of claims 13 to 21 wherein m is 1.
23. A compound of the formula (I) as defined in claim 1 selected from:
- 30 (RS)-1-(4-fluorobenzoyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(2-thienylcarbonyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-cyclopropylcarbonyl-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(2-furylcarbonyl)-3-(4-fluorobenzoyl)piperidine;

- (RS)-1-(morpholinocarbonyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(2-chlorobenzoyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(3-trifluoromethoxybenzoyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(4-difluoromethoxybenzoyl)-3-(4-fluorobenzoyl)piperidine;
5 (RS)-1-(4-isopropoxybenzoyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(2-quinolincarbonyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(4-fluorobenzenesulphonyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(2-thienylsulphonyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-isopropylsulphonyl-3-(4-fluorobenzoyl)piperidine;
10 (RS)-1-(2-trifluoromethylbenzenesulphonyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(1,2,5-thiadiazol-3-ylcarbonyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(cyclohexylcarbonyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(2-(4-fluorophenyl)acetyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(5-chloro-2-thienylcarbonyl)-3-(4-fluorobenzoyl)piperidine;
15 (RS)-1-(4-cyanobenzoyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(4-methoxybenzoyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(2,5-difluorobenzoyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(3-quinolincarbonyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(2-tetrahydrofurylcarbonyl)-3-(4-fluorobenzoyl)piperidine;
20 (RS)-1-(6-indolylcarbonyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(benzothien-2-ylcarbonyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(2-trifluoromethoxybenzoyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(4-ethoxybenzoyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(5-trifluoromethylfur-2-ylcarbonyl)-3-(4-fluorobenzoyl)piperidine;
25 (RS)-1-(4-trifluoromethoxybenzoyl)-3-(3-fluorobenzoyl)piperidine;
(RS)-1-(2-cyanobenzoyl)-3-(3-fluorobenzoyl)piperidine;
(RS)-1-(benzothien-2-ylcarbonyl)-3-(3-fluorobenzoyl)piperidine;
(RS)-1-(2,5-difluorobenzoyl)-3-(3-fluorobenzoyl)piperidine;
(RS)-1-(4-t-butoxybenzoyl)-3-(3,4-difluorobenzoyl)piperidine;
30 (RS)-1-(4-trifluoromethoxybenzoyl)-3-(3,4-difluorobenzoyl)piperidine;
(RS)-1-(4-methylaminobenzoyl)-3-(3,4-difluorobenzoyl)piperidine;
(RS)-1-(2-cyanobenzoyl)-3-(3,4-difluorobenzoyl)piperidine;
(RS)-1-(4-ethoxybenzoyl)-3-(3,4-difluorobenzoyl)piperidine;

- 53 -

- (RS)-1-(2,5-difluorobenzoyl)-3-(3,4-difluorobenzoyl)piperidine;
(RS)-1-(2-tetrahydrofurylcarbonyl)-3-(3,4-difluorobenzoyl)piperidine;
(RS)-1-(2-pyridylcarbonyl)-3-(4-fluorobenzoyl)piperidine;
(RS)-1-(2-cyanobenzoyl)-3-(4-fluorobenzoyl)piperidine;
5 (RS)-1-(4-t-butoxybenzoyl)-3-(3-fluorobenzoyl)piperidine;
(RS)-1-(2-trifluoromethoxybenzoyl)-3-(3-fluorobenzoyl)piperidine;
(RS)-1-(4-ethoxybenzoyl)-3-(3-fluorobenzoyl)piperidine;
(RS)-1-(benzothien-2-ylcarbonyl)-3-(3,4-difluorobenzoyl)piperidine;
(RS)-1-(2-trifluoromethoxybenzoyl)-3-(3,4-difluorobenzoyl)piperidine;
10 (RS)-1-(4-methoxybenzoyl)-3-(3,4-difluorobenzoyl)piperidine;
(RS)-1-(t-butyloxycarbonyl)-3-(3-fluorobenzoyl)piperidine;
(RS)-1-(t-butyloxycarbonyl)-3-(3,4-difluorobenzoyl)piperidine;
(RS)-1-(t-butyloxycarbonyl)-3-(4-fluorobenzoyl)piperidine;
(R)- or (S)-1-cyclohexylcarbonyl-3-(4-fluorobenzoyl)piperidine;
15 (S)- or (R)-1-cyclohexylcarbonyl-3-(4-fluorobenzoyl)piperidine;
cis-1-(4-fluorobenzoyl)-2-methyl-3-(4-fluorobenzoyl)piperidine; and
cis-1-(4-fluorobenzoyl)-2-methyl-3-(4-methoxybenzoyl)piperidine;
or a pharmaceutically acceptable salt thereof.

20 24. A pharmaceutical composition, which comprises a compound of formula (IA'), or a pharmaceutically acceptable salt thereof, as claimed in claim 13, in association with a pharmaceutically-acceptable diluent or carrier.

25 25. A compound of the formula (IA'), or a pharmaceutically acceptable salt thereof, as claimed in claims 13, for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.

26. A compound of the formula (IA'), or a pharmaceutically acceptable salt thereof, as claimed in claims 13, for use as a medicament.

30

27. The use of a compound of the formula (I) or (IA'), or a pharmaceutically acceptable salt thereof, as claimed in claims 1 or 13, in the manufacture of a medicament for use in the production of an 11 β HSD1 inhibitory effect in a warm-blooded animal, such as man.

28. The use as claimed in any one of claims 1-13 and 27 wherein production of, or producing an, 11β HSD1 inhibitory effect refers to the treatment of metabolic syndrome.

5 29. The use as claimed in any one of claims 1-13 and 27 wherein production of, or producing an, 11β HSD1 inhibitory effect refers to the treatment of diabetes, obesity, hyperlipidaemia, hyperglycaemia, hyperinsulinemia or hypertension, particularly diabetes and obesity.

10 30. The use as claimed in any one of claims 1-13 and 27 wherein production of, or producing an, 11β HSD1 inhibitory effect refers to the treatment of glaucoma, osteoporosis, tuberculosis, dementia, cognitive disorders or depression.

31. A method of producing an 11β HSD1 inhibitory effect in a warm-blooded animal, such
15 as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), as claimed in any one of claims 1-12, or a compound of formula (IA') as claimed in claim 13, or a pharmaceutically acceptable salt thereof.